Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

8.21
-0.1200-1.44%
Post-market: 8.10-0.1099-1.34%19:42 EDT
Volume:1.45M
Turnover:11.86M
Market Cap:460.87M
PE:-105.80
High:8.37
Open:8.29
Low:8.05
Close:8.33
52wk High:13.16
52wk Low:6.19
Shares:56.14M
Float Shares:47.46M
Volume Ratio:1.31
T/O Rate:3.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0776
EPS(LYR):-2.2813
ROE:3.53%
ROA:-18.85%
PB:3.93
PE(LYR):-3.60

Loading ...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

GlobeNewswire
·
Jul 28

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

GlobeNewswire
·
Jul 18

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

GlobeNewswire
·
Jul 16

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

GlobeNewswire
·
Jul 11

Zevra Therapeutics Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 10

Zevra Therapeutics Up Over 16%, on Track for Highest Close Since July 2021 -- Data Talk

Dow Jones
·
Jul 08

BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial

Reuters
·
Jul 03

BUZZ-U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier

Reuters
·
Jul 02

BUZZ-Zevra Therapeutics rises after H.C. Wainwright starts coverage with 'buy' rating

Reuters
·
Jul 02

Chief Legal & Compliance Officer Rahsaan Thompson Reports Disposal of Common Shares of Zevra Therapeutics Inc

Reuters
·
Jul 01

Press Release: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

Dow Jones
·
May 30

BRIEF-Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees

Reuters
·
May 21